MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Clinical trials for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS explained in plain language.
Never miss a new study
Get alerted when new MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS trials appear
Sign up with your email to follow new studies for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug HU6 targets fatty liver in Mid-Stage trial
Disease control Recruiting nowThis study tests a new drug, HU6, in 180 adults aged 30 and older with MASH, a type of fatty liver disease linked to metabolism. The goal is to see if HU6 is safe and can reduce liver fat over 26 weeks compared to a placebo. Participants will be randomly assigned to one of four g…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Rivus Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 01:59 UTC
-
Hope for advanced fatty liver: new drug trial targets cirrhosis
Disease control Recruiting nowThis study tests a new medicine called efruxifermin for people with advanced liver scarring (cirrhosis) caused by fatty liver disease (NASH/MASH). About 2,150 adults will receive either the drug or a placebo to see if it prevents serious liver events like liver failure. The goal …
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated May 17, 2026 01:50 UTC
-
Could a common heart pill treat fatty liver?
Disease control Recruiting nowThis study tests whether a low dose of digoxin, a drug normally used for heart problems, can help people with a severe type of fatty liver disease called NASH (also known as MASH). About 144 adults with confirmed NASH and liver scarring will take digoxin or a placebo for a period…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated May 17, 2026 01:49 UTC
-
New MASH drug trial aims to tame fatty liver disease
Disease control Recruiting nowThis early-stage study tests a new drug called TGM-312-SC01 in healthy adults and people with MASH, a type of fatty liver disease. The main goal is to check the drug's safety and how the body processes it. About 99 participants will receive either the drug or a placebo to gather …
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE1, PHASE2 • Sponsor: Tangram Therapeutics Plc • Aim: Disease control
Last updated May 17, 2026 01:46 UTC
-
New hope for transplant patients: drug targets return of fatty liver
Disease control Recruiting nowThis study tests an experimental drug called resmetirom in people who have had a liver transplant and later developed a fatty liver condition called MASH. About 120 participants will receive either the drug or a placebo for 28 weeks. The goal is to see if the drug can safely redu…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New hope for fatty liver: drug trial targets scarring
Disease control Recruiting nowThis study tests a drug called resmiterom in 165 adults with MASH, a type of fatty liver disease that can lead to scarring. Participants must have at least one metabolic issue like diabetes or obesity. The goal is to see if the drug safely reduces liver damage and improves thyroi…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE4 • Sponsor: Nabiqasim Industries (Pvt) Ltd • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
New study tracks Rezdiffra's safety in pregnant NASH patients and their infants
Knowledge-focused Recruiting nowThis study is a registry that follows women with NASH who took Rezdiffra during pregnancy or while breastfeeding, along with their babies up to 12 months old. The goal is to monitor pregnancy outcomes, birth defects, and infant growth and development. No new treatment is given—on…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated May 15, 2026 11:53 UTC
-
Fatty liver linked to colon polyp genes? new study investigates
Knowledge-focused Recruiting nowThis study looks at colon polyps in people with a type of fatty liver disease (MASH) compared to those without it. Researchers want to find specific gene patterns that might signal higher-risk polyps. About 100 adults already scheduled for routine colon polyp removal will donate …
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Sponsor: Shanghai East Hospital • Aim: Knowledge-focused
Last updated May 14, 2026 12:03 UTC